As we all know, the only constant in life is change. Change is a necessary part of evolution, and your practices should be no different. For example, age-related macular degeneration (AMD) has been around for decades, and the care protocols haven’t been updated much in those years. However, Craig Bowen, OD, shared how he keeps his procedures fresh in an article for Review of Optometric Business and talks about why you should consider updating yours.
Invest In Technology
As with most changes nowadays, technology will be involved in your AMD protocol updates. Dr. Bowen mentions the AdaptDX, which is a device that helps identify early signs of AMD. He likes it because:
- You can cover the cost with insurance reimbursements.
- It identifies patients much earlier than visual changes.
- It helps streamline the AMD identification process by eliminating the need to do in-depth testing on anyone and everyone.
- It adds an extra revenue stream for his practice.
Bowen has his patients complete a questionnaire to determine whether he should consider dark adaptation testing. From there, he’ll explain why he wants to perform the exam and why they should strongly consider taking it.
Another Tech Option
Another technology you can add to your AMD protocol is the QuantifEye® MPS II. The QuantifEye MPS II tests for low macular pigment optical density (MPOD), which is a key risk factor for AMD, as well as other eye health issues. This 2-minute, monocular exam doesn’t take up a lot of time or room in the testing lane, and there are affordable lease and purchase options. Unlike the AdaptDX, the QuantifEye identifies potential risk and assigns a score to that risk, which allows you to step in even earlier with lifestyle interventions.
Additionally, if you prescribe a carotenoid-based nutraceutical for your patients, this instrument can help track patients’ nutritional progress. With 95% repeatability and 99% accuracy, you can trust the results which are given as a simplified score for you and your patients to measure. When you partner with EyePromise, you have the option of including the QuantifEye in your practice, along with clinically validated nutraceuticals guaranteed to increase MPOD.
With every partnership, EyePromise offers personalized training, so you and your staff feel comfortable and confident with the program, the nutraceuticals, and the QuantifEye MPS II. Each system comes pre-installed with How-To videos for both staff and patients, in English and Spanish, to help reduce confusion and streamline the testing process.
Upgrade Your Nutritional Intervention
AMD care protocol has been the same for years, too. While the AREDS 2 clinical trial is still considered the gold standard, it was conducted nearly 15 years ago, leaving room for reevaluation and updates. EyePromise offers the most innovative, efficacious AMD nutraceutical line available for your patients and practice.
EyePromise AREDS Plus Multi-Vitamin is a comprehensive formula that includes the ingredients studied in the AREDS 2 clinical trial. However, it also includes additional ingredients demonstrated to benefit aging eyes or addressing unique risk factors for AMD. With a reduced zinc level based on the recommendations of the Institute of Medicine’s Food and Nutrition Board, this vitamin is the best option for patients you’ve identified with intermediate to advanced AMD.
If you use genetic testing in your practice, EyePromise also offers a unique AREDS 2 formula for patients who need to avoid zinc altogether. EyePromise AREDS 2 Plus Zinc-Free also includes the ingredients studied in the AREDS 2 trial minus the potentially harmful mineral. Like its multi-vitamin counterpart, this formula also includes the extra ingredients proven to positively impact aging eyes.
But what can you do for patients who are concerned about age-related eye health? EyePromise offers Restore, a formula designed for proactive nutritional intervention for these patient types. Clinically proven to increase MPOD and reduce other risk factors associated with AMD, Restore is the best option for your at-risk patients.
Good for Patients = Good for Practice
While these additions to your protocols are good for your practice, they are also good for your patients. Identifying issues early gives them a better outlook for the future and testing their progress with the nutraceuticals with the QuantifEye instrument helps keep them motivated. Additionally, Dr. Bowen explains,
“…when patients have a confirmed AMD diagnosis—as is often the case when we perform dark adaptation testing—it prompts me to educate the patient on how we can work together to preserve their vision.”